Search results
Nipah monoclonal antibody to undergo human trials in India, Bangladesh in 2025
IBTmes India· 13 hours agoA novel monoclonal antibody against the Nipah virus is set to undergo human clinical trials in...
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
Pharmaceutical Technology· 15 hours agoEli Lilly announced on 2 July 2024 that the US Food and Drug Administration (FDA) has approved its...
J&J looks to challenge argenx’s Vyvgart with positive Phase III data
Pharmaceutical Technology· 3 days agoThe company also plans to submit the data to regulatory agencies, later this year. Nipocalimab is an...
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
Pharmaceutical Technology· 1 day agoThe deal, which was agreed upon in May this year and includes $650m in milestone payments, sees...
USFDA approves Eli Lilly’s drug to treat Alzheimer’s in adults
Financial Express· 2 days agoThe United States Food and Drug Administration (USFDA) on Tuesday approved a new Alzheimer’s drug...
Sanofi reports findings from Phase II relapsing MS treatment trial
Clinical Trials Arena· 4 days agoSanofi has reported the latest data from a Phase II clinical trial of a cluster of differentiation...
Eisai and Bristol Myers Squibb terminate ADC development deal
Pharmaceutical Technology· 3 days agoThe remaining amount will be recorded as other income. FZEC combines Eisai’s humanised IgG1 ...
NIH announces start of Phase I enterovirus D68 therapeutic clinical trial
Clinical Trials Arena· 7 days agoThe US National Institutes of Health (NIH) has announced the commencement of a Phase I clinical...
EAN 2024: anti-CGRPs more effective than onabotulinumtoxinA in chronic migraine prevention in real...
Pharmaceutical Technology· 2 days agoChronic migraine is defined as patients who suffer 15 or more incidences of migraine per month...
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology· 3 days agoWith genomic medicine gaining clinical momentum, developers are looking for more robust ways to...